caspofungin
Experimental TherapeuticsThe Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida aurisThe in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition).
Letter to the EditorCaspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Mechanisms of ResistanceGenomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding YeastThere are only a few antifungal drugs used systemically in treatment, and invasive fungal infections that are resistant to these drugs are an emerging problem in health care. In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in ...
MinireviewEchinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to BedsideEchinocandins (caspofungin, micafungin, anidulafungin), targeting β-1,3-glucan synthesis of the cell wall, represent one of the three currently available antifungal drug classes for the treatment of invasive fungal infections. Despite their limited antifungal activity against Aspergillus spp., echinocandins are considered an alternative option for the treatment of invasive aspergillosis (IA).
PharmacologyBody Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory StudyWe evaluated the population pharmacokinetics of caspofungin in children (2 to 12 years of age). The real-world data from 48 children were best fit by a two-compartment model with first-order elimination.
Clinical TherapeuticsPharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin LevelsCaspofungin has a liver-dependent metabolism. Reduction of the dose is recommended based on Child-Pugh (C-P) score.
Mechanisms of ResistanceSpontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrataEchinocandins are front-line agents for treatment of invasive candidiasis. There are no reported agent-specific differences in Candida mutational frequency of resistance or propensity to develop FKS mutations.
- Mechanisms of ResistanceUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
- Experimental TherapeuticsAntifungal Activity of Oleylphosphocholine on In Vitro and In Vivo Candida albicans Biofilms